Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use.

artificial tears demulcents dry eye humectants ophthalmic preservatives osmoprotectants

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
21 Mar 2021
Historique:
received: 05 03 2021
revised: 15 03 2021
accepted: 18 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

Dry eye disease is a common ocular condition affecting millions of people worldwide. Artificial tears are the first line therapy for the management of dry eye disease. Artificial tear formulations contain a variety of active ingredients, biologically active excipients, and preservatives. Many of these formulations are also available as preservative-free. This study was conducted to inspect artificial tear formulations currently marketed in the United States for their active ingredients, biologically relevant excipients, and preservatives. The marketed artificial tears were examined at various US retail pharmacy chains and using the manufacturers' website to compile information about active ingredients, inactive ingredients, and preservatives. The currently marketed artificial tears can be grouped into four categories based on their active ingredients. The artificial tears also contain biologically active chemicals listed as inactive ingredients, which have osmoprotectant, humectant, and tear film lipid layer or mucous layer mimicking properties. Most artificial tears contain vanishing type preservatives such as purite or sodium perborate and safer quaternary compound polyquaternium-1. The majority of these artificial tear formulations are also available as preservative-free single dose unit. The study provides a formulary of artificial tears based on active ingredients, biologically active excipients, and the preservative-free option. The formulary should assist healthcare providers in making a stepwise and rational selection of appropriate artificial tears for patients suffering from dry eye disease.

Identifiants

pubmed: 33800965
pii: jcm10061289
doi: 10.3390/jcm10061289
pmc: PMC8003881
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Invest Ophthalmol Vis Sci. 2012 Apr 06;53(4):1792-802
pubmed: 22410563
Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2313-5
pubmed: 8505213
Eye (Lond). 1998;12 ( Pt 5):829-33
pubmed: 10070519
J Ocul Pharmacol. 1991 Spring;7(1):53-64
pubmed: 2061690
Cornea. 2007 Feb;26(2):175-81
pubmed: 17251808
Cont Lens Anterior Eye. 2019 Aug;42(4):443-449
pubmed: 30573298
Cornea. 1992 May;11(3):221-5
pubmed: 1587129
Am J Ophthalmol. 2017 Oct;182:90-98
pubmed: 28705660
Curr Eye Res. 2015 Jul;40(7):657-67
pubmed: 25271595
Eur J Ophthalmol. 2017 Jan 19;27(1):1-9
pubmed: 27445067
Mol Vis. 2014 Sep 12;20:1243-52
pubmed: 25352733
Cornea. 2015 Apr;34(4):421-6
pubmed: 25651494
J Ophthalmol. 2018 Mar 7;2018:1319628
pubmed: 29707390
Expert Opin Drug Deliv. 2011 Nov;8(11):1425-38
pubmed: 21905766
Int J Mol Sci. 2020 May 15;21(10):
pubmed: 32429217
Curr Eye Res. 2018 May;43(5):588-594
pubmed: 29388845
Adv Ther. 2001 Sep-Oct;18(5):205-15
pubmed: 11783457
Cornea. 2008 Jun;27(5):574-9
pubmed: 18520508
Adv Ther. 2011 Apr;28(4):311-25
pubmed: 21424577
J Ocul Pharmacol Ther. 2006 Aug;22(4):267-78
pubmed: 16910868
Ophthalmology. 2019 Jan;126(1):P286-P334
pubmed: 30366798
J Ocul Pharmacol Ther. 2011 Jun;27(3):273-80
pubmed: 21410334
Mol Vis. 2006 Apr 26;12:415-21
pubmed: 16688112
Curr Eye Res. 2011 Nov;36(11):979-88
pubmed: 21999224
Ocul Surf. 2017 Jul;15(3):366-403
pubmed: 28736338
Cont Lens Anterior Eye. 2018 Feb;41(1):60-68
pubmed: 28811095
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5503-11
pubmed: 26284556
Adv Ther. 2008 Aug;25(8):743-51
pubmed: 18670744
PLoS One. 2011;6(10):e26103
pubmed: 22022526
Optom Vis Sci. 2008 Aug;85(8):725-31
pubmed: 18677236
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1644-52
pubmed: 19168896
Clin Ophthalmol. 2011;5:783-90
pubmed: 21750611
Clin Ophthalmol. 2014 Jul 31;8:1419-33
pubmed: 25114502
Cont Lens Anterior Eye. 2010 Apr;33(2):76-82
pubmed: 19963428
Adv Ther. 2011 Jun;28(6):501-10
pubmed: 21603985
Biomed Res Int. 2014;2014:292139
pubmed: 24995283
Graefes Arch Clin Exp Ophthalmol. 2012 Sep;250(9):1333-40
pubmed: 22580989
J Ocul Pharmacol Ther. 2009 Apr;25(2):113-9
pubmed: 19284328
Invest Ophthalmol Vis Sci. 1999 Mar;40(3):619-30
pubmed: 10067965
Br J Ophthalmol. 1975 Nov;59(11):667-9
pubmed: 1203224
Exp Eye Res. 2009 Sep;89(3):311-8
pubmed: 19345212
Mol Vis. 2010 Sep 04;16:1823-31
pubmed: 21045919
Clin Ophthalmol. 2018 Mar 06;12:453-461
pubmed: 29563769
Curr Eye Res. 2004 Jun;28(6):437-44
pubmed: 15512952
Optometry. 2011 Jan;82(1):38-43
pubmed: 21146792
Cornea. 2004 Jul;23(5):490-6
pubmed: 15220734
Br J Ophthalmol. 2004 Jun;88(6):821-5
pubmed: 15148219
Cochrane Database Syst Rev. 2016 Feb 23;2:CD009729
pubmed: 26905373
Mol Vis. 2012;18:317-29
pubmed: 22355243
J Cell Biochem. 2000 Sep 18;80(1):1-10
pubmed: 11029749
Cornea. 2013 Dec;32(12):1599-606
pubmed: 24113372
Ocul Surf. 2017 Jul;15(3):269-275
pubmed: 28736334
J Ocul Pharmacol Ther. 2015 Oct;31(8):491-7
pubmed: 26067908
J Fr Ophtalmol. 2018 Feb;41(2):e51-e57
pubmed: 29366588
Ocul Surf. 2017 Jul;15(3):575-628
pubmed: 28736343
Curr Eye Res. 2000 Feb;20(2):85-94
pubmed: 10617908
Eur J Ophthalmol. 2007 May-Jun;17(3):341-9
pubmed: 17534814
Ocul Surf. 2017 Jul;15(3):276-283
pubmed: 28736335
Eye (Lond). 2017 Oct;31(10):1409-1416
pubmed: 28452989
Cutan Ocul Toxicol. 2017 Dec;36(4):336-342
pubmed: 28166658
Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2525-33
pubmed: 11581193
Mol Vis. 2012;18:1189-96
pubmed: 22605930
Ocul Surf. 2013 Oct;11(4):246-58
pubmed: 24112228
Br J Ophthalmol. 2001 May;85(5):610-2
pubmed: 11316726
Clin Ophthalmol. 2019 Aug 01;13:1409-1425
pubmed: 31447543
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4844-9
pubmed: 18641280
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):642-52
pubmed: 11222522
J Vet Med Sci. 2014 Sep;76(9):1219-24
pubmed: 24881653
Cutan Ocul Toxicol. 2015;34(3):195-202
pubmed: 25265260
Protein Sci. 2009 Jan;18(1):24-36
pubmed: 19177348

Auteurs

Avani Kathuria (A)

Chapman University School of Pharmacy, Chapman University, Irvine, CA 92618, USA.

Kiumars Shamloo (K)

Chapman University School of Pharmacy, Chapman University, Irvine, CA 92618, USA.

Vishal Jhanji (V)

Department of Ophthalmology, School of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Ajay Sharma (A)

Chapman University School of Pharmacy, Chapman University, Irvine, CA 92618, USA.

Classifications MeSH